drugset
drugset / Trial / NCT05659264

A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure

NCT05659264 ↗

Phase 1 Completed 48 enrolled ModernaTX, Inc.
RandomizedSequentialSingle-blindTreatment

Summary

The primary objective of this study is to evaluate the safety and tolerability of single and multiple doses at escalating dose levels of mRNA-0184.

Timeline

Start
2022-12-05
Primary completion
2024-12-17
Completion
2024-12-17

Drugs

EvaluationDrugModalityDoseRoute
Subject mRNA-0184 Unknown — Intravenous

Indications

heart failure